Id: acc0824
Group: 2sens
Protein: Ezrin
Gene Symbol: EZR
Protein Id: P15311
Protein Name: EZRI_HUMAN
PTM: phosphorylation
Site: Thr567
Site Sequence: MRQGRDKYKTLRQIRQGNTKQ
Disease Category: Cancer
Disease: Nasopharyngeal Carcinoma
Disease Subtype:
Disease Cellline: 5-8F
Disease Info:
Drug: berberine
Drug Info: "Berberine is a bioactive alkaloid derived from plants such as *Berberis vulgaris*, with demonstrated hypoglycemic, lipid-lowering, and antimicrobial effects, primarily mediated through AMP-activated protein kinase (AMPK) activation and gut microbiota modulation."
Effect: modulate
Effect Info: Berberine inhibits the metastasis of nasopharyngeal carcinoma 5 - 8F cells by reducing the phosphorylation of Ezrin (Thr567) mediated by Rho kinase.
Note:
Score: 4.0
Pubmed(PMID): 19651779
Sentence Index:
Sentence:

Sequence & Structure:

MPKPINVRVTTMDAELEFAIQPNTTGKQLFDQVVKTIGLREVWYFGLHYVDNKGFPTWLKLDKKVSAQEVRKENPLQFKFRAKFYPEDVAEELIQDITQKLFFLQVKEGILSDEIYCPPETAVLLGSYAVQAKFGDYNKEVHKSGYLSSERLIPQRVMDQHKLTRDQWEDRIQVWHAEHRGMLKDNAMLEYLKIAQDLEMYGINYFEIKNKKGTDLWLGVDALGLNIYEKDDKLTPKIGFPWSEIRNISFNDKKFVIKPIDKKAPDFVFYAPRLRINKRILQLCMGNHELYMRRRKPDTIEVQQMKAQAREEKHQKQLERQQLETEKKRRETVEREKEQMMREKEELMLRLQDYEEKTKKAERELSEQIQRALQLEEERKRAQEEAERLEADRMAALRAKEELERQAVDQIKSQEQLAAELAEYTAKIALLEEARRRKEDEVEEWQHRAKEAQDDLVKTKEELHLVMTAPPPPPPPVYEPVSYHVQESLQDEGAEPTGYSAELSSEGIRDDRNEEKRITEAEKNERVQRQLLTLSSELSQARDENKRTHNDIIHNENMRQGRDKYKTLRQIRQGNTKQRIDEFEAL

Select PDB:

Known Drugs:

source: Multi-Sources

(see table)

No data.

Protein Tractability:

source: Open Targets
Small molecule
Antibody
PROTAC
Other modalities
Approved Drug
Advanced Clinical
Phase 1 Clinical
Structure with Ligand
High-Quality Ligand
High-Quality Pocket
Med-Quality Pocket
Druggable Family
Approved Drug
Advanced Clinical
Phase 1 Clinical
UniProt loc high conf
GO CC high conf
UniProt loc med conf
UniProt SigP or TMHMM
GO CC med conf
Human Protein Atlas loc
Approved Drug
Advanced Clinical
Phase 1 Clinical
Literature
UniProt Ubiquitination
Database Ubiquitination
Half-life Data
Small Molecule Binder
Approved Drug
Advanced Clinical
Phase 1 Clinical

PTM Intensity:

source: CPTAC
EZR-Thr567
Cancer Intensity
BRCA
COAD
HGSC
ccRCC
GBM
HNSC
LUAD
LUSC
non_ccRCC
PDAC
UCEC

PTM-Disease Association:

source: PTMD
Residue Position State Disease Class PMID
T 567 P Nasopharyngeal carcinoma Phosphorylation 24649150 ;  19651779
T 567 P Squamous cell carcinoma Phosphorylation 23752190
T 567 U Nasopharyngeal carcinoma Phosphorylation 21873785
T 567 U Colorectal cancer Phosphorylation 31775562
T 567 U Esophageal squamous cell carcinoma Phosphorylation 31409639
T 567 U Glioma Phosphorylation 34540823

State Note: Based on the distinct PTM states in diseases, PTMD classified all disease-associated PTMs into six classes, including whether the up-regulation (U) or down-regulation (D) of PTM levels, the absence (A) or presence (P) of PTMs, and the creation (C) or disruption (N) of PTM sites are associated with diseases.

PTM-Drug Perturbation Response:

source: DecryptM

No data.

Function score:

source: funscoR

No data.

Cross Links: